血管內(nèi)皮生長因子B(VEGFB)重組蛋白
Recombinant Vascular Endothelial Growth Factor B (VEGFB)
VEGF-B; VEGFL; VRF; VEGF-Related Factor
- 編號RPA144Bo02
- 物種Bos taurus; Bovine (Cattle，牛) 相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位分泌
- 預測分子量49.0kDa
- 實際分子量49kDa(差異分析請參閱說明書)
- 片段與標簽Pro22~Arg188 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點9.3
-
應用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 984 ¥ 2460 ¥ 4920 ¥ 14760 ¥ 36900
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
SDS-PAGE圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Bos taurus; Bovine (Cattle，牛) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA144Bo02 | 血管內(nèi)皮生長因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA144Bo01 | 血管內(nèi)皮生長因子B(VEGFB)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA144Bo01 | 血管內(nèi)皮生長因子B(VEGFB)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA144Bo02 | 血管內(nèi)皮生長因子B(VEGFB)多克隆抗體 | WB; IHC; ICC; IP. |
參考文獻
| 雜志 | 參考文獻 |
| International Journal of Cardiology | Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. [PubMed: 22459379] |
| Applied Sciences-Basel | Assessment of annexin A5 and annexin A2 levels as biomarkers for pre-eclampsia: A pilot study [pubmed:29099033] |
| Journal of Endocrinological Investigation | Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell [10.1007/s40618-017-0677-z] |
| EXCLI Journal | Plasma vascular endothelial growth factor B is elevated in non-alcoholic fatty liver disease patients and associated with blood pressure and renal dysfunction [] |
| Cancer Chemother Pharmacol | Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors [34164713] |
留言咨詢
